VistaGen Therapeutics, Inc. (VSTA) Targeting Nation’s No. 1 VistaGen Therapeutics, Inc. (VSTA) Targeting Nation’s No. 1 Killer with Proprietary 3D Bioassay System
Despite decades of awareness and prevention campaigns, heart disease remains the No. 1 cause of death for both men and women, killing more than 600,000 Americans each year. Roughly 49 percent of Americans have at least one of the three risk factors for heart disease: high blood pressure, high LDL cholesterol and smoking, according to the Center for Disease Control. What’s astounding is that an overwhelming majority of heart disease is the result of poor lifestyle choices. While it’s certainly nothing to celebrate, the statistics are keeping scientists on their toes and companies like VistaGen in business.
VistaGen is an innovative life sciences company leveraging its Human Clinical Trials in a Test Tube™ technology platform to provide clinically relevant predictions of potential toxicity of promising new drug candidates. One of VistaGen’s particular areas of focus is on cardiovascular care.
It is estimated that about one-third of all potential new drugs candidates fail in preclinical or clinical development due to unexpected safety concerns. Countless human lives have been lost because “promising” cardiovascular drugs were discontinued because of late-stage failure. Using human heart cells derived from human pluripotent stem cells (hPSCs), VistaGen’s technology is designed to address potential toxicity of new cardiovascular drug candidates long before they are ever tested in humans.
CardioSafe 3D™, the company’s novel three-dimensional (3D) bioassay system, was developed to identify safer drug rescue variants with reduced heart safety concerns, which can be missed in animal models or in vitro cell culture testing currently used by biotechnology and pharmaceutical companies.
VistaGen’s strategy is to pair CardioSafe 3D™ with modern medicinal chemistry to build a pipeline of novel, safer chemical variants (Drug Rescue Variants™) of once-promising drug candidates that initially were developed by biotechnology and pharmaceutical companies, but that were later abandoned due to the aforementioned concerns.
The core goal is to license or sell Drug Rescue Variants to biotechnology and pharmaceutical companies for further development and commercialization. VistaGen believes its strategy has the potential to substantially reduce drug development costs and produce effective and safer drugs, which would inherently help save human lives.
For more information visit www.vistagen.com
Please read full disclaimers at https://disclaimer.missionir.com